Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Over half of refractory AML patients responded to combo

Advani A et al. ASH 2017, Abstract 150.

Key clinical point: MEC plus ixazomib is well tolerated and effective in relapsed/refractory AML.

Major finding: The overall response rate was 53%.

Study details: A phase 1 trial involving 30 patients.

Disclosures: Dr. Advani reported receiving research funding from Takeda/Millenium, and serving as a consultant for Pfizer.

Source: Advani A et al. ASH 2017, Abstract 150.

Read the full article.

Citation:

Advani A et al. ASH 2017, Abstract 150.

This Week's Must Reads

Policy statement on access to opioid medications, Statement on Opioid Use in Patients with Hematologic Diseases and Disorders, American Society of Hematology

FDA approves Mircera for dialysis-related anemia in pediatric patients, FDA approved-drug notice, June 7, 2018; Mircena label (Drugs@FDA)

FDA approves pembrolizumab for relapsed/refractory PMBCL, FDA Press Announcement, June 15, 2018; Keytruda Prescribing Information (Drugs@FDA)

Poor adherence to DOAC therapy requires attention, Lakkireddy D et al. Heart Rhythm 2018, Abstract B-LBCT02-03.

Red cell tranfusion may increase risk of postsurgical VTE, Goel R et al. JAMA Surg. 2018 Jun 13. doi: 10.1001/jamasurg.2018.1565

Must Reads in AML

One-third of IDH1-mutated AML cases have complete response to ivosidenib , Pollyea DA, et al. J Clin Oncol 36, 2018 (suppl) annual meeting of the American Society of Clinical Oncology; abstr 7000.

New option for IDH1-mutated AML, Pollyea DA, et al. J Clin Oncol 36, 2018 (suppl; abstr 7000).

Adding statin boosted AML response rate, Advani AS et al. Leuk Res. 2018 Apr;67:17-20.

Pembrolizumab after cytarabine boosts AML response, Zeidner J et al. Acute Leukemia Forum 2018, Poster Session.

Over half of refractory AML patients responded to combo, Advani A et al. ASH 2017, Abstract 150.